Metraipolis › archive › dc_efaae1ba8b80

Comparative safety and effectiveness of Pfizer BA.4-5 versus Sanofi during the spring 2023 COVID-19 booster vaccination programme in England: a matched cohort… — Europe PMC PPR:PPR822686

Source
Europe PMC
Original
https://europepmc.org/article/PPR/PPR822686
DOI
10.1101/2024.03.15.24304277
License (as archived)
solo-consultazione
Archived
2026-10-07T22:22:03.076Z
SHA-256 of the archived text
713e4cb1c97cedfd09bc6aecd161827da4a5fd092636197b1ee1331dcf97cb2e
Stable URL of this page
https://metraipolis.com/documento/dc_efaae1ba8b80

How to cite

Comparative safety and effectiveness of Pfizer BA.4-5 versus Sanofi during the spring 2023 COVID-19 booster vaccination programme in England: a matched cohort… — Europe PMC PPR:PPR822686 — Europe PMC, https://europepmc.org/article/PPR/PPR822686 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_efaae1ba8b80 (Metraipolis archive dc_efaae1ba8b80, sha256 713e4cb1c97cedfd09bc6aecd161827da4a5fd092636197b1ee1331dcf97cb2e)
BibTeX
@misc{dcefaae1ba8b80,
  title = {Comparative safety and effectiveness of Pfizer BA.4-5 versus Sanofi during the spring 2023 COVID-19 booster vaccination programme in England: a matched cohort… — Europe PMC PPR:PPR822686},
  howpublished = {Europe PMC},
  url = {https://europepmc.org/article/PPR/PPR822686},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_efaae1ba8b80; sha256 713e4cb1c97cedfd09bc6aecd161827da4a5fd092636197b1ee1331dcf97cb2e},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/PPR/PPR822686. Agents can read the archived copy with the MCP tool read_document.